[go: up one dir, main page]

MX2019012033A - Regímenes de dosificación y composiciones y métodos relacionados. - Google Patents

Regímenes de dosificación y composiciones y métodos relacionados.

Info

Publication number
MX2019012033A
MX2019012033A MX2019012033A MX2019012033A MX2019012033A MX 2019012033 A MX2019012033 A MX 2019012033A MX 2019012033 A MX2019012033 A MX 2019012033A MX 2019012033 A MX2019012033 A MX 2019012033A MX 2019012033 A MX2019012033 A MX 2019012033A
Authority
MX
Mexico
Prior art keywords
compstatin analogs
aspects
cell
methods
complement
Prior art date
Application number
MX2019012033A
Other languages
English (en)
Inventor
Francois Cedric
Deschatelets Pascal
Grossi Federico
Johnson Patrick
Vega Carolina
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of MX2019012033A publication Critical patent/MX2019012033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/148—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons flexible, e.g. independent bags
    • A61M5/152—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons flexible, e.g. independent bags pressurised by contraction of elastic reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)

Abstract

En algunos aspectos la presente invención se refiere, a análogos de compstatina de células reactivas y composiciones que comprenden análogos de compstatina de células reactivas En algunos aspectos, la invención además proporciona 'métodos para usar análogos de compstatina de células reactivas, por ejemplo, para tratar un trastorno mediado por el complemento, por ejemplo, para inhibir el daño mediado por el complemento a una célula, tejido, u órgano. En algunos aspectos, la invención proporciona análogos de compstatina de acción prolongada y composiciones que comprenden análogos de compstatina de acción prolongada. En algunos aspectos, la invención además proporciona métodos para usar análogos de compstatina de acción prolongada, por ejemplo, para tratar el trastorno mediado por el complemento, por ejemplo, para inhibir el daño mediado por el complemento a una célula, tejido, u órgano. En algunos aspectos, la invención proporciona análogos de compstatina objetivo y composiciones que comprenden análogos de compstatina objetivo. En algunos aspectos, la invención además proporciona métodos para usar análogos de compstatina objetivo, por ejemplo, para inhibir el daño mediado por el complemento a una célula, tejido u órgano.
MX2019012033A 2017-04-07 2018-04-09 Regímenes de dosificación y composiciones y métodos relacionados. MX2019012033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483295P 2017-04-07 2017-04-07
US201762485343P 2017-04-13 2017-04-13
PCT/US2018/026753 WO2018187813A1 (en) 2017-04-07 2018-04-09 Dosing regimens and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2019012033A true MX2019012033A (es) 2019-12-05

Family

ID=63712642

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012033A MX2019012033A (es) 2017-04-07 2018-04-09 Regímenes de dosificación y composiciones y métodos relacionados.
MX2024010865A MX2024010865A (es) 2017-04-07 2019-10-07 Composiciones de analogos de compstatina de accion prolongada y su uso en regimenes de dosificacion para tratar trastornos mediados por el complemento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024010865A MX2024010865A (es) 2017-04-07 2019-10-07 Composiciones de analogos de compstatina de accion prolongada y su uso en regimenes de dosificacion para tratar trastornos mediados por el complemento.

Country Status (11)

Country Link
US (3) US11040107B2 (es)
EP (2) EP4585228A3 (es)
JP (3) JP2020516607A (es)
KR (2) KR20190139931A (es)
CN (2) CN116059313A (es)
AU (2) AU2018249627B2 (es)
BR (1) BR112019020955A2 (es)
CA (1) CA3059304A1 (es)
IL (3) IL269844B2 (es)
MX (2) MX2019012033A (es)
WO (1) WO2018187813A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2915265T3 (es) 2011-05-11 2022-06-21 Apellis Pharmaceuticals Inc Análogos de compstatina reactivos con células, de acción prolongada o dirigidos y usos de los mismos
BR112015011244B1 (pt) * 2012-11-15 2022-08-09 Apellis Pharmaceuticals, Inc Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
EP4585228A3 (en) 2017-04-07 2025-10-15 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
JP2023509520A (ja) * 2020-01-07 2023-03-08 アペリス・ファーマシューティカルズ・インコーポレイテッド 発作性夜間ヘモグロビン尿症の治療
US20250000936A1 (en) * 2021-09-09 2025-01-02 Apellis Pharmaceuticals, Inc. Treatment of geographic atrophy
CN116459342A (zh) * 2023-03-27 2023-07-21 中国人民解放军总医院海南医院 一种用于急性心肌梗死闭塞血管远端的溶栓组合物

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5157110A (en) 1988-08-20 1992-10-20 The Government Of The United States Of America Synthetic, anti-complement protein
IL95942A0 (en) 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5492135A (en) 1992-09-09 1996-02-20 Devore; Dale P. Collagen modulators for use in photoablation excimer laser keratectomy
US5482135A (en) 1993-06-29 1996-01-09 Deere & Company Combined hydraulic reservoir and vehicle axle
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH08280800A (ja) 1995-04-12 1996-10-29 Nissho Corp ２液注射用プレフィルドシリンジ
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
EP0894002A4 (en) 1996-03-13 2001-11-14 Univ Pennsylvania NEW PEPTIDES TO INHIBIT COMPLEMENT ACTIVATION
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
WO1997047321A1 (en) 1996-06-14 1997-12-18 The Johns Hopkins University School Of Medicine Use of chimeric vaccinia virus complement control proteins to inhibit complement
JPH1087700A (ja) 1996-06-17 1998-04-07 Smithkline Beecham Corp Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO1998047002A2 (en) 1997-04-11 1998-10-22 Advanced Medicine, Inc. Polyvalent presenter combinatorial libraries and their uses
JP2002503223A (ja) 1997-04-11 2002-01-29 アドバンスト・メディシン・インコーポレイテッド 複数の活性分子を供与する分子
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JPH11197234A (ja) 1998-01-09 1999-07-27 Koken Co Ltd 眼科用コラーゲンゲル成形物
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7084106B1 (en) 1999-01-19 2006-08-01 University Of Louisville Research Foundation, Inc. Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease
US6645177B1 (en) 1999-02-09 2003-11-11 Alaris Medical Systems, Inc. Directly engaged syringe driver system
AU3856400A (en) 1999-02-12 2000-08-29 Collagenesis, Inc. Injectable collagen-based system for delivery of cells or therapeutic agents
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
GB9910985D0 (en) 1999-05-12 1999-07-14 Smiths Industries Plc Syringe pumps
AU5158000A (en) 1999-05-25 2000-12-12 King Faisal Specialist Hospital And Research Centre Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
IT1307266B1 (it) 1999-08-13 2001-10-30 Cane Srl Apparecchio per infusione di farmaci.
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
ES2316446T3 (es) 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
WO2002011793A1 (fr) 2000-08-08 2002-02-14 Medical Information Services, Inc. Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
ATE401919T1 (de) 2000-11-09 2008-08-15 Insulet Corp Gerät zur transkutanen abgabe von medikamenten
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
AU2002241834B2 (en) 2001-01-09 2006-11-09 Microchips, Inc. Flexible microchip devices for opthalmic and other applications
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20050054596A1 (en) 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
TWI260327B (en) 2001-11-09 2006-08-21 Osi Eyetech Inc Pharmaceutical compositions for treating ocular neovascular diseases
JP2005538033A (ja) 2001-12-04 2005-12-15 ナノスペクトラ バイオサイエンセズ，インク． 過剰なあるいは不適切な新脈管形成によって特徴付けられる病状の治療
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
US7150724B2 (en) 2002-06-05 2006-12-19 Cardinal Health 303, Inc. Syringe plunger driver system
US7018361B2 (en) 2002-06-14 2006-03-28 Baxter International Inc. Infusion pump
US20040092470A1 (en) 2002-06-18 2004-05-13 Leonard Sherry A. Dry powder oligonucleotide formualtion, preparation and its uses
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP3976635B2 (ja) 2002-08-05 2007-09-19 久光製薬株式会社 キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤
ES2373649T3 (es) 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
US20060251621A1 (en) 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
AU2003284304B8 (en) 2002-10-21 2009-08-06 Nagler, Richard Surface coating comprising bioactive compound
AU2003301813A1 (en) 2002-10-30 2004-06-07 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006518749A (ja) 2003-02-21 2006-08-17 タノックス インコーポレーテッド 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法
EP1594541A4 (en) 2003-02-21 2007-03-28 Rikshospitalet Radiumhospitale METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20070116672A1 (en) 2003-09-05 2007-05-24 Kotwal Girish J Treatment of rheumatic diseases
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
PT1713503E (pt) 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
LT2860251T (lt) 2004-02-12 2018-07-10 Archemix Llc Aptamero terapija, naudinga gydant su komplementu susijusias ligas
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
AU2005244061A1 (en) 2004-05-10 2005-11-24 Novacea, Inc. Prevention of arterial restenosis with active vitamin D compounds
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
WO2006042252A2 (en) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
CA2588270A1 (en) 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
WO2006099330A2 (en) 2005-03-11 2006-09-21 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
US8329652B2 (en) * 2005-05-10 2012-12-11 Neoloch Aps Neuritogenic peptides
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
WO2007047626A1 (en) 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
EP2500030B2 (en) 2005-11-04 2018-08-08 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
CN101346473A (zh) 2005-12-22 2009-01-14 爱尔康研究有限公司 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂
EP1803934B1 (en) 2005-12-28 2008-09-24 Sensile Pat AG Micropump
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
KR101470679B1 (ko) 2007-07-19 2014-12-08 올엑셀, 인크. 항암제로서의 자기 조립형 양친매성 중합체
US20110092446A1 (en) 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
US8088884B2 (en) 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
RU2505311C2 (ru) 2007-10-02 2014-01-27 Потентия Фармасьютикалз, Инк. Пролонгированная доставка аналогов компстатина из гелей
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
KR101486449B1 (ko) 2008-01-11 2015-01-26 세리나 쎄라퓨틱스, 인코포레이티드 다작용성 형태의 폴리옥시졸린 공중합체 및 이를 포함하는 약물 조성물
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CN102149749B (zh) 2008-07-10 2014-06-25 塞瑞纳治疗公司 具有惰性端基的聚噁唑啉、由被保护的引发基团制备的聚噁唑啉以及相关化合物
NO2424557T3 (es) 2009-05-01 2018-03-24
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
US8765973B2 (en) 2009-07-10 2014-07-01 The General Hospital Corporation Etomidate analogues that do not inhibit adrenocortical steroid synthesis
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
EP2552518A4 (en) 2010-04-01 2014-08-13 Enable Injections Llc DEVICE AND SYSTEM FOR INJECTION OF MEDICAL LIQUIDS
US8625635B2 (en) 2010-04-26 2014-01-07 Cleversafe, Inc. Dispersed storage network frame protocol header
IT1404942B1 (it) 2010-06-11 2013-12-09 Cane Spa Dispositivo per l'infusione simultanea di farmaci in piu' siti di infusione.
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012006599A2 (en) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
WO2012040259A2 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
IT1403780B1 (it) 2010-12-02 2013-10-31 Cane Spa Dispositivo per l'infusione di farmaci.
ES2915265T3 (es) 2011-05-11 2022-06-21 Apellis Pharmaceuticals Inc Análogos de compstatina reactivos con células, de acción prolongada o dirigidos y usos de los mismos
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PT2753636T (pt) 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US20160067357A1 (en) 2012-08-17 2016-03-10 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US20150217058A1 (en) 2012-09-24 2015-08-06 Enable Injections, Llc Medical vial and injector assemblies and methods of use
WO2014078734A2 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
BR112015011244B1 (pt) 2012-11-15 2022-08-09 Apellis Pharmaceuticals, Inc Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
ITMI20122263A1 (it) * 2012-12-28 2014-06-29 Azienda Ospedaliero Universitaria Di Parma Nuovi peptidi cationici ciclici ad attività antimicrobica
CA2901012C (en) 2013-02-15 2021-07-06 Repro-Med Systems, Inc. Multi-flow universal tubing set
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3023126B1 (en) 2013-07-16 2021-01-27 Beijing Mechanical Equipment Institute Fire engine suitable for fire-fighting in high-rise and super high-rise buildings
ITTO20130661A1 (it) 2013-08-02 2015-02-03 Cane Spa Pompa portatile per l¿infusione di sostanze liquide nel corpo di un essere vivente e serbatoio per l¿uso in detta pompa
US9806963B2 (en) 2013-10-18 2017-10-31 Cellco Partnership Feature activation on device
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2015142701A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
WO2016049385A1 (en) * 2014-09-24 2016-03-31 Apellis Pharmaceuticals, Inc. Methods and compositions for cancer treatment and treatment selection
JP6968787B2 (ja) * 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
MX2019004500A (es) * 2016-10-17 2019-08-21 Apellis Pharmaceuticals Inc Terapia de combinación para la inhibición de componente de complemeto (c3).
EP4585228A3 (en) 2017-04-07 2025-10-15 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
AU2018386304B2 (en) * 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2021007111A1 (en) * 2019-07-05 2021-01-14 Apellis Pharmaceuticals, Inc. Viral vector therapy

Also Published As

Publication number Publication date
BR112019020955A2 (pt) 2020-05-05
JP2025118761A (ja) 2025-08-13
MX2024010865A (es) 2024-09-23
US20210401997A1 (en) 2021-12-30
US20200038516A1 (en) 2020-02-06
IL314891A (en) 2024-10-01
JP2023100641A (ja) 2023-07-19
IL269844B2 (en) 2025-01-01
AU2025205058A1 (en) 2025-07-24
RU2019131869A (ru) 2021-05-07
CN110831544A (zh) 2020-02-21
KR20240135047A (ko) 2024-09-10
IL269844B1 (en) 2024-09-01
IL269844A (en) 2019-11-28
EP4585228A2 (en) 2025-07-16
IL323564A (en) 2025-11-01
EP4585228A3 (en) 2025-10-15
US11844841B2 (en) 2023-12-19
CA3059304A1 (en) 2018-10-11
AU2018249627B2 (en) 2025-04-03
JP2020516607A (ja) 2020-06-11
EP3606465A4 (en) 2021-03-24
EP3606465A1 (en) 2020-02-12
CN110831544B (zh) 2022-11-18
US20240285783A1 (en) 2024-08-29
WO2018187813A1 (en) 2018-10-11
CN116059313A (zh) 2023-05-05
KR20190139931A (ko) 2019-12-18
AU2018249627A1 (en) 2019-10-31
IL314891B1 (en) 2025-11-01
RU2019131869A3 (es) 2021-07-09
US11040107B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
MX2019012033A (es) Regímenes de dosificación y composiciones y métodos relacionados.
MX2019007709A (es) Analogos de compstatina de celula reactiva, de accion prolongada u objetivos y composiciones y metodos relacionados.
MX2022005370A (es) Analogos de compstatina de accion prolongada para usarse en el tratamiento de trastornos oculares.
MX385001B (es) Analogos de compstatina de celula reactiva, de accion prolongada u objetivos y usos de los mismos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2019003283A1 (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas.
UY40064A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
BR112013028907A2 (pt) conjugados de proteína-agente ativo e método para preparar os mesmos
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX392977B (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
GT201400043A (es) Imidazopiridazinas sustituidas con amino
MX2018003551A (es) Composicion limpiadora auto-espumante para enjuagar que contiene ivermectina.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
CO2017010151A2 (es) Material de implante compuesto
BR112014013374A2 (pt) formulações de acamprosato, métodos de usar o mesmo, e as combinações que compõem o mesmo
MX378539B (es) Analagos de apelina ciclicos.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
AR099405A1 (es) Composición antifúngica tópica para el tratamiento de onicomicosis
MX2015016093A (es) Trans-clomifeno y sus analogos como agentes que aumentan la densidad mineral osea.
AR096390A1 (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO